Three years after Ann Arbor, MI-based Atterocor got started with a lead program for adrenal cancer, the biotech is now ready to launch into its next big stage of development after in-licensing a mid-stage drug from AstraZeneca and raising a whopping $62 million round with plans to roll out a slate of new studies. And the developer will be operating under a new and more easily handled name: Millendo Therapeutics.
With an eye to jumping into the clinic with a lead drug for muscle wasting while building up a pipeline of drugs that target key growth factors, Scholar Rock is refueling for its next stage of development with a $36 million B round from a group of investors led by Fidelity Management and Research.
More than two years after landing a hefty launch round, San Diego-based eFFECTOR Therapeutics has scooped up a $40 million financing from an expanded group of investors, putting the biotech on track to jump into the clinic with a Phase I/II study of its lead cancer drug.
OrbiMed has come through with a whopping $950 million biotech venture fund, committing anywhere from $10 million to a hefty $75 million to each of about 30 new companies.
George Vlasuk and his biotech crew at Navitor have lined up a $33 million round designed to get the first snapshot on clinical efficacy for its platform play.
WuXi PharmaTech, China's largest CRO, closed an oversubscribed $290 million venture fund, turning its attention to biopharma startups at home and in the U.S.
Roche-partnered epigenetic specialist Oryzon Genomics has listed its shares on the Madrid Stock Exchange. The biotech went public by listing all its shares on the exchange rather than offering stock to investors, leaving it with the same market cap and bank balance as when it raised €16.5 million ($18.1 million) in a rights issue earlier this year.
GamaMabs Pharma has raised €15 million ($16.4 million) to advance a monoclonal antibody against gynecological cancers into the clinic and up to proof-of-concept. Edmond de Rothschild Investment Partners' BioDiscovery 4 came on board to lead the Series B round.
Over the last 18 months Genzyme founder Henri Termeer has been helping organize and finance a new biotech called X4, which has taken up residence in Cambridge, MA, and is now going public with a $37.5 million A round and a plan to make its mark in the hot field of immuno-oncology.
The Wellcome Trust's investment arm is putting up £25 million ($38 million) to launch a new company developing a potential one-time treatment for hemophilia and planning to build a pipeline of gene therapies.